4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation

摘要

Mycobacterial DNA gyrase B subunit has been identified to be one of the potentially underexploited drug targets in the field of antitubercular drug discovery. In the present study, we employed structural optimization of the reported GyrB inhibitor resulting in synthesis of a series of 46 novel quinoline derivatives. The compounds were evaluated for their in vitro Mycobacterium smegmatis GyrB inhibitory ability and Mycobacterium tuberculosis DNA supercoiling inhibitory activity. The antitubercular activity of these compounds was tested over Mtb H37Rv strain and their safety profile was checked against mouse macrophage RAW 264.7 cell line. Among all, three compounds (23, 28, and 53) emerged to be active displaying IC50 values below 1 mu M against Msm GyrB and were found to be non-cytotoxic at 50 mu M concentration. Compound 53 was identified to be potent GyrB inhibitor with 0.86 +/- 0.16 mu M and an MIC (minimum inhibitory concentration) of 3.3 mu M. The binding affinity of this compound towards GyrB protein was analysed by differential scanning fluorimetry which resulted in a positive shift of 3.3 degrees C in melting temperature (T-m) when compared to the native protein thereby reacertaining the stabilization effect of the compound over protein. (C) 2015 Elsevier Masson SAS. All rights reserved.